Obermatt
See Similar Stocks →

ImageneBio

NAQ:IMA · US45175G2075
PharmaceuticalsSmall

360

22
Medium confidence — indicative
Profit price80
Owner Earnings Yield98
Dividend Yield1
Price/Sales39
Price/Book74
Return on Capital14
Return on Equity8
Profit margins4

Cash truth not applicable for financial companies.

Sales growth1
Profit growth80
Reinvestment4
Price momentum6
Debt load65
Debt serviceability99
Liquidity42
Analyst ratings3
Opinion Changes50
Price Target Upside57
Market mood3
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

ImageneBio doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 1/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Websiteinmagenebio.com
ISINUS45175G2075
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyInflammationOncologyBiopharmaBiotechnologyHealth Care

Description

ImageneBio, Inc. (ImageneBio) is a clinical-stage biopharmaceutical company. The company develops therapeutics for patients with immunological, autoimmune, and inflammatory diseases. IMG-007 is a non-depleting anti-OX40 monoclonal antibody that bin…

Analysis

Middle-of-the-road

ImageneBio, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is adequate. The company scores 0/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
7
2023202420252026

All-time high

42

Jan 2024

All-time low

7

Mar 2026

Average rank

24

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
39
1
11
8
Price/Earnings
5
36
36
36
Price/Book
74
79
78
74
Dividend Yield
1
1
1
1
Value (overall)
56
26
36
31

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare ImageneBio with its peers
Shattuck Labs
NSQ:STTK
50
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Acumen Pharmaceuticals
NSQ:ABOS
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Actuate Therapeutics
NMQ:ACTU
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Zenas Biopharma
NSQ:ZBIO
42
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Dianthus Therapeutics
NAQ:DNTH
20
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tango Therapeutics
NMQ:TNGX
16
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →